Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| HALOZYME THERAPEUTICS, INC.HALO · Entity 793 | SVP, GC | April 13, 2019 | April 15, 2019 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
HALOZYME THERAPEUTICS, INC.
Report date April 13, 2019 · Filed April 15, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 66,373 |
Ending reported balance
After 2019-04-13 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2019-04-13 · Exercise / conversion · Acquired 6,875 · Balance 68,750 Row 2 · 2019-04-13 · Tax withholding · Disposed 2,377 · Balance 66,373 F1: The reported disposition of 2,377 shares represents the shares that were withheld by the Issuer as payment for minimum statutory tax withholding requirements. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 0 |
Reported balance
After 2019-04-13 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2019-04-13 · Exercise / conversion · Disposed 6,875 · Balance 0 F2: This transaction represents the vesting and settlement of restricted stock units in shares of common stock of the Issuer. |
Filing footnotes · ownership attribution and instrument terms
F1: The reported disposition of 2,377 shares represents the shares that were withheld by the Issuer as payment for minimum statutory tax withholding requirements.
F2: This transaction represents the vesting and settlement of restricted stock units in shares of common stock of the Issuer.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Poseida Therapeutics, Inc.
Report date January 08, 2025 · Filed January 08, 2025
Section 16 reporting ended · disclosed 2025-01-08. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2025-01-08 transaction · row 1
1 source rowRow 1 · 2025-01-08 · Other · Disposed 223,640 · Balance 0 F1: Disposed of pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of November 25, 2024, by and among Poseida Therapeutics, Inc. (the "Issuer"), Roche Holdings, Inc. ("Parent") and Blue Giant Acquisition Corp., a wholly owned subsidiary of Parent ("Merger Sub"). On January 8, 2025, Parent and Merger Sub completed a tender offer pursuant to the terms of the Merger Agreement for all outstanding shares of common stock of the Issuer (each, a "Share") for an offer price of (i) $9.00 per Share in cash (the "Cash Amount"), and (ii) one non-tradeable contingent value right (each, a "CVR") representing the right to receive certain contingent payments of up to an aggregate amount of $4.00 per Share, [continues to Footnote 2] F2: [continues from Footnote 1] in cash, upon the achievement of specified milestones, subject to and in accordance with the terms of the Contingent Value Rights Agreement (the "CVR Agreement"), in each case, without interest, and subject to any applicable withholding taxes (the Cash Amount plus one CVR, collectively, the "Offer Price"). Merger Sub thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent (the "Merger"). At the effective time of the Merger, each issued and outstanding Share (other than any Excluded Shares (as such term is defined in the Merger Agreement)) was cancelled in exchange for the right to receive the Offer Price. F3: Includes 3,000 shares acquired by the Reporting Person under the Issuer's 2020 Employee Stock Purchase Plan (the "ESPP") on March 20, 2024, 3,000 shares acquired by the Reporting Person under the ESPP on September 20, 2024 and 3,000 shares acquired by the Reporting Person under the ESPP on January 2, 2025. |
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $16.00 · Expires 2030-07-08 | Direct | 0 |
Reported balance
After 2025-01-08 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2025-01-08 · Disposition to issuer · Disposed 160,385 · Balance 0 F4: As of immediately prior to and conditioned upon the effective time of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option to purchase Shares (each, an "Option") became fully vested and exercisable, and to the extent not exercised prior to the effective time of the Merger, was cancelled and converted into the right to receive (a) an amount in cash (without interest and subject to deduction for any required withholding tax) equal to the product of (1) the excess, if any, of the Cash Amount over the exercise price per share of each such Option and (2) the number of Shares underlying such Option immediately prior to the effective time of the Merger and (b) one CVR in respect of each Share underlying such Option (the "Option Consideration"); provided, however, that if the exercise price per Share of any Option was equal to or greater than the Cash Amount, but less than $13.00 (any such option, an "Underwater Option"), [continues to Footnote 5] F5: [Continues from Footnote 4] such Underwater Option was not entitled to any payment of the Cash Amount in respect thereof and each Underwater Option was converted into the right to receive the CVR included in the Option Consideration with respect to each Share underlying such Underwater Option and became entitled to receive, at each time a milestone payment becomes due and payable under the terms of the CVR Agreement, an amount in cash equal to the product of (a) the total number of Shares underlying such Underwater Option, multiplied by (b) the amount, if any, by which (1) the Cash Amount plus the amount of such milestone payment plus the amount of any other milestone payments that previously became due and payable under the terms of the CVR Agreement exceeds (2) the exercise price per Share with respect to such Underwater Option plus the Milestone Payment Amounts (as such term is defined in the CVR Agreement), [continues to Footnote 6] F6: [Continues from Footnote 5] if any, previously paid pursuant to the CVR Agreement in respect of each CVR granted in respect of such Underwater Option; provided further, that any Option with an exercise price that was equal to or greater than $13.00, was cancelled immediately prior to the effective time of the Merger without any payment being made in respect thereof. |
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.15 · Expires 2031-02-03 | Direct | 0 |
Reported balance
After 2025-01-08 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2025-01-08 · Disposition to issuer · Disposed 137,000 · Balance 0 F4: As of immediately prior to and conditioned upon the effective time of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option to purchase Shares (each, an "Option") became fully vested and exercisable, and to the extent not exercised prior to the effective time of the Merger, was cancelled and converted into the right to receive (a) an amount in cash (without interest and subject to deduction for any required withholding tax) equal to the product of (1) the excess, if any, of the Cash Amount over the exercise price per share of each such Option and (2) the number of Shares underlying such Option immediately prior to the effective time of the Merger and (b) one CVR in respect of each Share underlying such Option (the "Option Consideration"); provided, however, that if the exercise price per Share of any Option was equal to or greater than the Cash Amount, but less than $13.00 (any such option, an "Underwater Option"), [continues to Footnote 5] F5: [Continues from Footnote 4] such Underwater Option was not entitled to any payment of the Cash Amount in respect thereof and each Underwater Option was converted into the right to receive the CVR included in the Option Consideration with respect to each Share underlying such Underwater Option and became entitled to receive, at each time a milestone payment becomes due and payable under the terms of the CVR Agreement, an amount in cash equal to the product of (a) the total number of Shares underlying such Underwater Option, multiplied by (b) the amount, if any, by which (1) the Cash Amount plus the amount of such milestone payment plus the amount of any other milestone payments that previously became due and payable under the terms of the CVR Agreement exceeds (2) the exercise price per Share with respect to such Underwater Option plus the Milestone Payment Amounts (as such term is defined in the CVR Agreement), [continues to Footnote 6] F6: [Continues from Footnote 5] if any, previously paid pursuant to the CVR Agreement in respect of each CVR granted in respect of such Underwater Option; provided further, that any Option with an exercise price that was equal to or greater than $13.00, was cancelled immediately prior to the effective time of the Merger without any payment being made in respect thereof. |
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.42 · Expires 2032-02-28 | Direct | 0 |
Reported balance
After 2025-01-08 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2025-01-08 · Disposition to issuer · Disposed 72,568 · Balance 0 F4: As of immediately prior to and conditioned upon the effective time of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option to purchase Shares (each, an "Option") became fully vested and exercisable, and to the extent not exercised prior to the effective time of the Merger, was cancelled and converted into the right to receive (a) an amount in cash (without interest and subject to deduction for any required withholding tax) equal to the product of (1) the excess, if any, of the Cash Amount over the exercise price per share of each such Option and (2) the number of Shares underlying such Option immediately prior to the effective time of the Merger and (b) one CVR in respect of each Share underlying such Option (the "Option Consideration"); provided, however, that if the exercise price per Share of any Option was equal to or greater than the Cash Amount, but less than $13.00 (any such option, an "Underwater Option"), [continues to Footnote 5] F5: [Continues from Footnote 4] such Underwater Option was not entitled to any payment of the Cash Amount in respect thereof and each Underwater Option was converted into the right to receive the CVR included in the Option Consideration with respect to each Share underlying such Underwater Option and became entitled to receive, at each time a milestone payment becomes due and payable under the terms of the CVR Agreement, an amount in cash equal to the product of (a) the total number of Shares underlying such Underwater Option, multiplied by (b) the amount, if any, by which (1) the Cash Amount plus the amount of such milestone payment plus the amount of any other milestone payments that previously became due and payable under the terms of the CVR Agreement exceeds (2) the exercise price per Share with respect to such Underwater Option plus the Milestone Payment Amounts (as such term is defined in the CVR Agreement), [continues to Footnote 6] F6: [Continues from Footnote 5] if any, previously paid pursuant to the CVR Agreement in respect of each CVR granted in respect of such Underwater Option; provided further, that any Option with an exercise price that was equal to or greater than $13.00, was cancelled immediately prior to the effective time of the Merger without any payment being made in respect thereof. |
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.35 · Expires 2033-02-28 | Direct | 0 |
Reported balance
After 2025-01-08 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2025-01-08 · Disposition to issuer · Disposed 125,283 · Balance 0 F4: As of immediately prior to and conditioned upon the effective time of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option to purchase Shares (each, an "Option") became fully vested and exercisable, and to the extent not exercised prior to the effective time of the Merger, was cancelled and converted into the right to receive (a) an amount in cash (without interest and subject to deduction for any required withholding tax) equal to the product of (1) the excess, if any, of the Cash Amount over the exercise price per share of each such Option and (2) the number of Shares underlying such Option immediately prior to the effective time of the Merger and (b) one CVR in respect of each Share underlying such Option (the "Option Consideration"); provided, however, that if the exercise price per Share of any Option was equal to or greater than the Cash Amount, but less than $13.00 (any such option, an "Underwater Option"), [continues to Footnote 5] F5: [Continues from Footnote 4] such Underwater Option was not entitled to any payment of the Cash Amount in respect thereof and each Underwater Option was converted into the right to receive the CVR included in the Option Consideration with respect to each Share underlying such Underwater Option and became entitled to receive, at each time a milestone payment becomes due and payable under the terms of the CVR Agreement, an amount in cash equal to the product of (a) the total number of Shares underlying such Underwater Option, multiplied by (b) the amount, if any, by which (1) the Cash Amount plus the amount of such milestone payment plus the amount of any other milestone payments that previously became due and payable under the terms of the CVR Agreement exceeds (2) the exercise price per Share with respect to such Underwater Option plus the Milestone Payment Amounts (as such term is defined in the CVR Agreement), [continues to Footnote 6] F6: [Continues from Footnote 5] if any, previously paid pursuant to the CVR Agreement in respect of each CVR granted in respect of such Underwater Option; provided further, that any Option with an exercise price that was equal to or greater than $13.00, was cancelled immediately prior to the effective time of the Merger without any payment being made in respect thereof. |
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.13 · Expires 2034-02-28 | Direct | 0 |
Reported balance
After 2025-01-08 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2025-01-08 · Disposition to issuer · Disposed 111,700 · Balance 0 F4: As of immediately prior to and conditioned upon the effective time of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option to purchase Shares (each, an "Option") became fully vested and exercisable, and to the extent not exercised prior to the effective time of the Merger, was cancelled and converted into the right to receive (a) an amount in cash (without interest and subject to deduction for any required withholding tax) equal to the product of (1) the excess, if any, of the Cash Amount over the exercise price per share of each such Option and (2) the number of Shares underlying such Option immediately prior to the effective time of the Merger and (b) one CVR in respect of each Share underlying such Option (the "Option Consideration"); provided, however, that if the exercise price per Share of any Option was equal to or greater than the Cash Amount, but less than $13.00 (any such option, an "Underwater Option"), [continues to Footnote 5] F5: [Continues from Footnote 4] such Underwater Option was not entitled to any payment of the Cash Amount in respect thereof and each Underwater Option was converted into the right to receive the CVR included in the Option Consideration with respect to each Share underlying such Underwater Option and became entitled to receive, at each time a milestone payment becomes due and payable under the terms of the CVR Agreement, an amount in cash equal to the product of (a) the total number of Shares underlying such Underwater Option, multiplied by (b) the amount, if any, by which (1) the Cash Amount plus the amount of such milestone payment plus the amount of any other milestone payments that previously became due and payable under the terms of the CVR Agreement exceeds (2) the exercise price per Share with respect to such Underwater Option plus the Milestone Payment Amounts (as such term is defined in the CVR Agreement), [continues to Footnote 6] F6: [Continues from Footnote 5] if any, previously paid pursuant to the CVR Agreement in respect of each CVR granted in respect of such Underwater Option; provided further, that any Option with an exercise price that was equal to or greater than $13.00, was cancelled immediately prior to the effective time of the Merger without any payment being made in respect thereof. |
Filing footnotes · ownership attribution and instrument terms
F1: Disposed of pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of November 25, 2024, by and among Poseida Therapeutics, Inc. (the "Issuer"), Roche Holdings, Inc. ("Parent") and Blue Giant Acquisition Corp., a wholly owned subsidiary of Parent ("Merger Sub"). On January 8, 2025, Parent and Merger Sub completed a tender offer pursuant to the terms of the Merger Agreement for all outstanding shares of common stock of the Issuer (each, a "Share") for an offer price of (i) $9.00 per Share in cash (the "Cash Amount"), and (ii) one non-tradeable contingent value right (each, a "CVR") representing the right to receive certain contingent payments of up to an aggregate amount of $4.00 per Share, [continues to Footnote 2]
F2: [continues from Footnote 1] in cash, upon the achievement of specified milestones, subject to and in accordance with the terms of the Contingent Value Rights Agreement (the "CVR Agreement"), in each case, without interest, and subject to any applicable withholding taxes (the Cash Amount plus one CVR, collectively, the "Offer Price"). Merger Sub thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent (the "Merger"). At the effective time of the Merger, each issued and outstanding Share (other than any Excluded Shares (as such term is defined in the Merger Agreement)) was cancelled in exchange for the right to receive the Offer Price.
F3: Includes 3,000 shares acquired by the Reporting Person under the Issuer's 2020 Employee Stock Purchase Plan (the "ESPP") on March 20, 2024, 3,000 shares acquired by the Reporting Person under the ESPP on September 20, 2024 and 3,000 shares acquired by the Reporting Person under the ESPP on January 2, 2025.
F4: As of immediately prior to and conditioned upon the effective time of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option to purchase Shares (each, an "Option") became fully vested and exercisable, and to the extent not exercised prior to the effective time of the Merger, was cancelled and converted into the right to receive (a) an amount in cash (without interest and subject to deduction for any required withholding tax) equal to the product of (1) the excess, if any, of the Cash Amount over the exercise price per share of each such Option and (2) the number of Shares underlying such Option immediately prior to the effective time of the Merger and (b) one CVR in respect of each Share underlying such Option (the "Option Consideration"); provided, however, that if the exercise price per Share of any Option was equal to or greater than the Cash Amount, but less than $13.00 (any such option, an "Underwater Option"), [continues to Footnote 5]
F5: [Continues from Footnote 4] such Underwater Option was not entitled to any payment of the Cash Amount in respect thereof and each Underwater Option was converted into the right to receive the CVR included in the Option Consideration with respect to each Share underlying such Underwater Option and became entitled to receive, at each time a milestone payment becomes due and payable under the terms of the CVR Agreement, an amount in cash equal to the product of (a) the total number of Shares underlying such Underwater Option, multiplied by (b) the amount, if any, by which (1) the Cash Amount plus the amount of such milestone payment plus the amount of any other milestone payments that previously became due and payable under the terms of the CVR Agreement exceeds (2) the exercise price per Share with respect to such Underwater Option plus the Milestone Payment Amounts (as such term is defined in the CVR Agreement), [continues to Footnote 6]
F6: [Continues from Footnote 5] if any, previously paid pursuant to the CVR Agreement in respect of each CVR granted in respect of such Underwater Option; provided further, that any Option with an exercise price that was equal to or greater than $13.00, was cancelled immediately prior to the effective time of the Merger without any payment being made in respect thereof.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 08, 2025 Filed Jan 8, 2025 14:09 UTC | Poseida Therapeutics, Inc. PSTX · Entity 84243 | Disposition to issuerEmployee Stock Option (Right to Buy) · Derivative | 111,700 | $0.00 Strike: $4.13 | $0.00 |
DisclosureSEC source: 0001415889-25-001082 · form4-01082025_070142.xml · derivative · entry 6 LEONHARDT HARRY J · CIK 0001286102 · GC & Chief Compliance Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 111,700 shares Expires 2034-02-28 F4 · derivative.exercise_date: As of immediately prior to and conditioned upon the effective time of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option to purchase Shares (each, an "Option") became fully vested and exercisable, and to the extent not exercised prior to the effective time of the Merger, was cancelled and converted into the right to receive (a) an amount in cash (without interest and subject to deduction for any required withholding tax) equal to the product of (1) the excess, if any, of the Cash Amount over the exercise price per share of each such Option and (2) the number of Shares underlying such Option immediately prior to the effective time of the Merger and (b) one CVR in respect of each Share underlying such Option (the "Option Consideration"); provided, however, that if the exercise price per Share of any Option was equal to or greater than the Cash Amount, but less than $13.00 (any such option, an "Underwater Option"), [continues to Footnote 5] F5 · derivative.exercise_date: [Continues from Footnote 4] such Underwater Option was not entitled to any payment of the Cash Amount in respect thereof and each Underwater Option was converted into the right to receive the CVR included in the Option Consideration with respect to each Share underlying such Underwater Option and became entitled to receive, at each time a milestone payment becomes due and payable under the terms of the CVR Agreement, an amount in cash equal to the product of (a) the total number of Shares underlying such Underwater Option, multiplied by (b) the amount, if any, by which (1) the Cash Amount plus the amount of such milestone payment plus the amount of any other milestone payments that previously became due and payable under the terms of the CVR Agreement exceeds (2) the exercise price per Share with respect to such Underwater Option plus the Milestone Payment Amounts (as such term is defined in the CVR Agreement), [continues to Footnote 6] F6 · derivative.exercise_date: [Continues from Footnote 5] if any, previously paid pursuant to the CVR Agreement in respect of each CVR granted in respect of such Underwater Option; provided further, that any Option with an exercise price that was equal to or greater than $13.00, was cancelled immediately prior to the effective time of the Merger without any payment being made in respect thereof. Read SEC document |
| January 08, 2025 Filed Jan 8, 2025 14:09 UTC | Poseida Therapeutics, Inc. PSTX · Entity 84243 | Disposition to issuerEmployee Stock Option (Right to Buy) · Derivative | 125,283 | $0.00 Strike: $5.35 | $0.00 |
DisclosureSEC source: 0001415889-25-001082 · form4-01082025_070142.xml · derivative · entry 5 LEONHARDT HARRY J · CIK 0001286102 · GC & Chief Compliance Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 125,283 shares Expires 2033-02-28 F4 · derivative.exercise_date: As of immediately prior to and conditioned upon the effective time of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option to purchase Shares (each, an "Option") became fully vested and exercisable, and to the extent not exercised prior to the effective time of the Merger, was cancelled and converted into the right to receive (a) an amount in cash (without interest and subject to deduction for any required withholding tax) equal to the product of (1) the excess, if any, of the Cash Amount over the exercise price per share of each such Option and (2) the number of Shares underlying such Option immediately prior to the effective time of the Merger and (b) one CVR in respect of each Share underlying such Option (the "Option Consideration"); provided, however, that if the exercise price per Share of any Option was equal to or greater than the Cash Amount, but less than $13.00 (any such option, an "Underwater Option"), [continues to Footnote 5] F5 · derivative.exercise_date: [Continues from Footnote 4] such Underwater Option was not entitled to any payment of the Cash Amount in respect thereof and each Underwater Option was converted into the right to receive the CVR included in the Option Consideration with respect to each Share underlying such Underwater Option and became entitled to receive, at each time a milestone payment becomes due and payable under the terms of the CVR Agreement, an amount in cash equal to the product of (a) the total number of Shares underlying such Underwater Option, multiplied by (b) the amount, if any, by which (1) the Cash Amount plus the amount of such milestone payment plus the amount of any other milestone payments that previously became due and payable under the terms of the CVR Agreement exceeds (2) the exercise price per Share with respect to such Underwater Option plus the Milestone Payment Amounts (as such term is defined in the CVR Agreement), [continues to Footnote 6] F6 · derivative.exercise_date: [Continues from Footnote 5] if any, previously paid pursuant to the CVR Agreement in respect of each CVR granted in respect of such Underwater Option; provided further, that any Option with an exercise price that was equal to or greater than $13.00, was cancelled immediately prior to the effective time of the Merger without any payment being made in respect thereof. Read SEC document |
| January 08, 2025 Filed Jan 8, 2025 14:09 UTC | Poseida Therapeutics, Inc. PSTX · Entity 84243 | Disposition to issuerEmployee Stock Option (Right to Buy) · Derivative | 72,568 | $0.00 Strike: $3.42 | $0.00 |
DisclosureSEC source: 0001415889-25-001082 · form4-01082025_070142.xml · derivative · entry 4 LEONHARDT HARRY J · CIK 0001286102 · GC & Chief Compliance Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 72,568 shares Expires 2032-02-28 F4 · derivative.exercise_date: As of immediately prior to and conditioned upon the effective time of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option to purchase Shares (each, an "Option") became fully vested and exercisable, and to the extent not exercised prior to the effective time of the Merger, was cancelled and converted into the right to receive (a) an amount in cash (without interest and subject to deduction for any required withholding tax) equal to the product of (1) the excess, if any, of the Cash Amount over the exercise price per share of each such Option and (2) the number of Shares underlying such Option immediately prior to the effective time of the Merger and (b) one CVR in respect of each Share underlying such Option (the "Option Consideration"); provided, however, that if the exercise price per Share of any Option was equal to or greater than the Cash Amount, but less than $13.00 (any such option, an "Underwater Option"), [continues to Footnote 5] F5 · derivative.exercise_date: [Continues from Footnote 4] such Underwater Option was not entitled to any payment of the Cash Amount in respect thereof and each Underwater Option was converted into the right to receive the CVR included in the Option Consideration with respect to each Share underlying such Underwater Option and became entitled to receive, at each time a milestone payment becomes due and payable under the terms of the CVR Agreement, an amount in cash equal to the product of (a) the total number of Shares underlying such Underwater Option, multiplied by (b) the amount, if any, by which (1) the Cash Amount plus the amount of such milestone payment plus the amount of any other milestone payments that previously became due and payable under the terms of the CVR Agreement exceeds (2) the exercise price per Share with respect to such Underwater Option plus the Milestone Payment Amounts (as such term is defined in the CVR Agreement), [continues to Footnote 6] F6 · derivative.exercise_date: [Continues from Footnote 5] if any, previously paid pursuant to the CVR Agreement in respect of each CVR granted in respect of such Underwater Option; provided further, that any Option with an exercise price that was equal to or greater than $13.00, was cancelled immediately prior to the effective time of the Merger without any payment being made in respect thereof. Read SEC document |
| January 08, 2025 Filed Jan 8, 2025 14:09 UTC | Poseida Therapeutics, Inc. PSTX · Entity 84243 | Disposition to issuerEmployee Stock Option (Right to Buy) · Derivative | 137,000 | $0.00 Strike: $9.15 | $0.00 |
DisclosureSEC source: 0001415889-25-001082 · form4-01082025_070142.xml · derivative · entry 3 LEONHARDT HARRY J · CIK 0001286102 · GC & Chief Compliance Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 137,500 shares Expires 2031-02-03 F4 · derivative.exercise_date: As of immediately prior to and conditioned upon the effective time of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option to purchase Shares (each, an "Option") became fully vested and exercisable, and to the extent not exercised prior to the effective time of the Merger, was cancelled and converted into the right to receive (a) an amount in cash (without interest and subject to deduction for any required withholding tax) equal to the product of (1) the excess, if any, of the Cash Amount over the exercise price per share of each such Option and (2) the number of Shares underlying such Option immediately prior to the effective time of the Merger and (b) one CVR in respect of each Share underlying such Option (the "Option Consideration"); provided, however, that if the exercise price per Share of any Option was equal to or greater than the Cash Amount, but less than $13.00 (any such option, an "Underwater Option"), [continues to Footnote 5] F5 · derivative.exercise_date: [Continues from Footnote 4] such Underwater Option was not entitled to any payment of the Cash Amount in respect thereof and each Underwater Option was converted into the right to receive the CVR included in the Option Consideration with respect to each Share underlying such Underwater Option and became entitled to receive, at each time a milestone payment becomes due and payable under the terms of the CVR Agreement, an amount in cash equal to the product of (a) the total number of Shares underlying such Underwater Option, multiplied by (b) the amount, if any, by which (1) the Cash Amount plus the amount of such milestone payment plus the amount of any other milestone payments that previously became due and payable under the terms of the CVR Agreement exceeds (2) the exercise price per Share with respect to such Underwater Option plus the Milestone Payment Amounts (as such term is defined in the CVR Agreement), [continues to Footnote 6] F6 · derivative.exercise_date: [Continues from Footnote 5] if any, previously paid pursuant to the CVR Agreement in respect of each CVR granted in respect of such Underwater Option; provided further, that any Option with an exercise price that was equal to or greater than $13.00, was cancelled immediately prior to the effective time of the Merger without any payment being made in respect thereof. Read SEC document |
| January 08, 2025 Filed Jan 8, 2025 14:09 UTC | Poseida Therapeutics, Inc. PSTX · Entity 84243 | Disposition to issuerEmployee Stock Option (Right to Buy) · Derivative | 160,385 | $0.00 Strike: $16.00 | $0.00 |
DisclosureSEC source: 0001415889-25-001082 · form4-01082025_070142.xml · derivative · entry 2 LEONHARDT HARRY J · CIK 0001286102 · GC & Chief Compliance Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 160,385 shares Expires 2030-07-08 F4 · derivative.exercise_date: As of immediately prior to and conditioned upon the effective time of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option to purchase Shares (each, an "Option") became fully vested and exercisable, and to the extent not exercised prior to the effective time of the Merger, was cancelled and converted into the right to receive (a) an amount in cash (without interest and subject to deduction for any required withholding tax) equal to the product of (1) the excess, if any, of the Cash Amount over the exercise price per share of each such Option and (2) the number of Shares underlying such Option immediately prior to the effective time of the Merger and (b) one CVR in respect of each Share underlying such Option (the "Option Consideration"); provided, however, that if the exercise price per Share of any Option was equal to or greater than the Cash Amount, but less than $13.00 (any such option, an "Underwater Option"), [continues to Footnote 5] F5 · derivative.exercise_date: [Continues from Footnote 4] such Underwater Option was not entitled to any payment of the Cash Amount in respect thereof and each Underwater Option was converted into the right to receive the CVR included in the Option Consideration with respect to each Share underlying such Underwater Option and became entitled to receive, at each time a milestone payment becomes due and payable under the terms of the CVR Agreement, an amount in cash equal to the product of (a) the total number of Shares underlying such Underwater Option, multiplied by (b) the amount, if any, by which (1) the Cash Amount plus the amount of such milestone payment plus the amount of any other milestone payments that previously became due and payable under the terms of the CVR Agreement exceeds (2) the exercise price per Share with respect to such Underwater Option plus the Milestone Payment Amounts (as such term is defined in the CVR Agreement), [continues to Footnote 6] F6 · derivative.exercise_date: [Continues from Footnote 5] if any, previously paid pursuant to the CVR Agreement in respect of each CVR granted in respect of such Underwater Option; provided further, that any Option with an exercise price that was equal to or greater than $13.00, was cancelled immediately prior to the effective time of the Merger without any payment being made in respect thereof. Read SEC document |
| January 08, 2025 Filed Jan 8, 2025 14:09 UTC | Poseida Therapeutics, Inc. PSTX · Entity 84243 | OtherCommon Stock | 223,640 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-25-001082 · form4-01082025_070142.xml · nonDerivative · entry 1 LEONHARDT HARRY J · CIK 0001286102 · GC & Chief Compliance Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · shares: Disposed of pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of November 25, 2024, by and among Poseida Therapeutics, Inc. (the "Issuer"), Roche Holdings, Inc. ("Parent") and Blue Giant Acquisition Corp., a wholly owned subsidiary of Parent ("Merger Sub"). On January 8, 2025, Parent and Merger Sub completed a tender offer pursuant to the terms of the Merger Agreement for all outstanding shares of common stock of the Issuer (each, a "Share") for an offer price of (i) $9.00 per Share in cash (the "Cash Amount"), and (ii) one non-tradeable contingent value right (each, a "CVR") representing the right to receive certain contingent payments of up to an aggregate amount of $4.00 per Share, [continues to Footnote 2] F2 · shares: [continues from Footnote 1] in cash, upon the achievement of specified milestones, subject to and in accordance with the terms of the Contingent Value Rights Agreement (the "CVR Agreement"), in each case, without interest, and subject to any applicable withholding taxes (the Cash Amount plus one CVR, collectively, the "Offer Price"). Merger Sub thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent (the "Merger"). At the effective time of the Merger, each issued and outstanding Share (other than any Excluded Shares (as such term is defined in the Merger Agreement)) was cancelled in exchange for the right to receive the Offer Price. F3 · shares: Includes 3,000 shares acquired by the Reporting Person under the Issuer's 2020 Employee Stock Purchase Plan (the "ESPP") on March 20, 2024, 3,000 shares acquired by the Reporting Person under the ESPP on September 20, 2024 and 3,000 shares acquired by the Reporting Person under the ESPP on January 2, 2025. F1 · price: Disposed of pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of November 25, 2024, by and among Poseida Therapeutics, Inc. (the "Issuer"), Roche Holdings, Inc. ("Parent") and Blue Giant Acquisition Corp., a wholly owned subsidiary of Parent ("Merger Sub"). On January 8, 2025, Parent and Merger Sub completed a tender offer pursuant to the terms of the Merger Agreement for all outstanding shares of common stock of the Issuer (each, a "Share") for an offer price of (i) $9.00 per Share in cash (the "Cash Amount"), and (ii) one non-tradeable contingent value right (each, a "CVR") representing the right to receive certain contingent payments of up to an aggregate amount of $4.00 per Share, [continues to Footnote 2] F2 · price: [continues from Footnote 1] in cash, upon the achievement of specified milestones, subject to and in accordance with the terms of the Contingent Value Rights Agreement (the "CVR Agreement"), in each case, without interest, and subject to any applicable withholding taxes (the Cash Amount plus one CVR, collectively, the "Offer Price"). Merger Sub thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent (the "Merger"). At the effective time of the Merger, each issued and outstanding Share (other than any Excluded Shares (as such term is defined in the Merger Agreement)) was cancelled in exchange for the right to receive the Offer Price. Read SEC document |
| March 01, 2024 Filed Mar 4, 2024 17:18 UTC | Poseida Therapeutics, Inc. PSTX · Entity 84243 | GrantEmployee Stock Option (Right to Buy) · Derivative | 111,700 | $0.00 Strike: $4.13 | $0.00 |
DisclosureSEC source: 0000950170-24-024921 · ownership.xml · derivative · entry 3 LEONHARDT HARRY J · CIK 0001286102 · GC & Chief Compliance Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 111,700 Underlying: Common Stock · 111,700 shares Expires 2034-02-28 F4 · derivative.exercise_date: 12.5% of the shares subject to the stock option will vest and become exercisable on the six-month anniversary of the grant date listed in column 3 above, and the remaining shares will vest in 42 equal monthly installments thereafter. Read SEC document |
| March 01, 2024 Filed Mar 4, 2024 17:18 UTC | Poseida Therapeutics, Inc. PSTX · Entity 84243 | Tax withholdingCommon Stock | 16,306 | $4.13 | $67,343.78 |
DisclosureSEC source: 0000950170-24-024921 · ownership.xml · nonDerivative · entry 2 LEONHARDT HARRY J · CIK 0001286102 · GC & Chief Compliance Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 214,640 F3 · shares: Represents shares withheld by the Issuer to satisfy income tax obligations associated with the vesting of Restricted Stock Unit Awards granted to the Reporting Person on March 1, 2022 and March 1, 2023. Read SEC document |
| March 01, 2024 Filed Mar 4, 2024 17:18 UTC | Poseida Therapeutics, Inc. PSTX · Entity 84243 | GrantCommon Stock | 80,743 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-024921 · ownership.xml · nonDerivative · entry 1 LEONHARDT HARRY J · CIK 0001286102 · GC & Chief Compliance Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 230,946 F1 · kind: Represents shares issuable upon the vesting of restricted stock units granted pursuant to the Issuer's Equity Incentive Plan. The RSUs are scheduled to vest in four equal annual installments. F2 · balance_after: Includes 3,000 shares acquired by the Reporting Person under the Issuer's 2020 Employee Stock Purchase Plan (the "ESPP") on March 20, 2023 and 3,000 shares acquired by the Reporting Person under the ESPP on September 20, 2023. Read SEC document |
| March 01, 2023 Filed Mar 2, 2023 18:26 UTC | Poseida Therapeutics, Inc. PSTX · Entity 84243 | GrantEmployee Stock Option (Right to Buy) · Derivative | 125,283 | $0.00 Strike: $5.35 | $0.00 |
DisclosureSEC source: 0001209191-23-014906 · doc4.xml · derivative · entry 3 LEONHARDT HARRY J · CIK 0001286102 · GC & Chief Compliance Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,283 Underlying: Common Stock · 125,283 shares Expires 2033-02-28 F4 · derivative.exercise_date: 12.5% of the shares subject to the stock option will vest and became exercisable on the six-month anniversary of the grant date listed in column 3 above, and the remaining shares will vest in 42 equal monthly installments thereafter. Read SEC document |
| March 01, 2023 Filed Mar 2, 2023 18:26 UTC | Poseida Therapeutics, Inc. PSTX · Entity 84243 | Tax withholdingCommon Stock | 4,323 | $5.35 | $23,128.05 |
DisclosureSEC source: 0001209191-23-014906 · doc4.xml · nonDerivative · entry 2 LEONHARDT HARRY J · CIK 0001286102 · GC & Chief Compliance Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 144,203 F3 · shares: Represents shares withheld by the Issuer to satisfy income tax obligations associated with the vesting of a Restricted Stock Unit Award granted to the Reporting Person on March 1, 2022. Read SEC document |
| March 01, 2023 Filed Mar 2, 2023 18:26 UTC | Poseida Therapeutics, Inc. PSTX · Entity 84243 | GrantCommon Stock | 92,772 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-014906 · doc4.xml · nonDerivative · entry 1 LEONHARDT HARRY J · CIK 0001286102 · GC & Chief Compliance Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 148,526 F1 · kind: Represents shares issuable upon the vesting of restricted stock units granted pursuant to the Issuer's Equity Incentive Plan. The RSUs are scheduled to vest in four equal annual installments. F2 · balance_after: Includes 2,482 shares acquired by the Reporting Person under the Issuer's 2020 Employee Stock Purchase Plan (the "ESPP") on September 20, 2021; 3,000 shares acquired by the Reporting Person under the ESPP on March 18, 2022, and 272 shares acquired by the Reporting Person under the ESPP on September 20, 2022. Read SEC document |
| March 01, 2022 Filed Mar 1, 2022 19:30 UTC | Poseida Therapeutics, Inc. PSTX · Entity 84243 | GrantEmployee Stock Option (Right to Buy) · Derivative | 72,568 | $0.00 Strike: $3.42 | $0.00 |
DisclosureSEC source: 0001209191-22-014378 · doc4.xml · derivative · entry 2 LEONHARDT HARRY J · CIK 0001286102 · GC & Chief Compliance Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,568 Underlying: Common Stock · 72,568 shares Expires 2032-02-29 F2 · derivative.exercise_date: 12.5% of the shares subject to the stock option will vest and become exercisable on the six-month anniversary of the grant date listed in column 3 above, and the remaining shares will vest in 42 equal monthly installments thereafter. Read SEC document |
| March 01, 2022 Filed Mar 1, 2022 19:30 UTC | Poseida Therapeutics, Inc. PSTX · Entity 84243 | GrantCommon Stock | 50,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-014378 · doc4.xml · nonDerivative · entry 1 LEONHARDT HARRY J · CIK 0001286102 · GC & Chief Compliance Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 F1 · kind: Represents restricted stock units granted pursuant to the Issuer's Equity Incentive Plan. The RSUs are scheduled to vest in four equal annual installments. Read SEC document |
| February 04, 2021 Filed Feb 5, 2021 16:54 UTC | Poseida Therapeutics, Inc. PSTX · Entity 84243 | GrantEmployee Stock Option (Right to Buy) · Derivative | 137,000 | $0.00 Strike: $9.15 | $0.00 |
DisclosureSEC source: 0001209191-21-008138 · doc4.xml · derivative · entry 1 LEONHARDT HARRY J · CIK 0001286102 · GC & Chief Compliance Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 137,000 Underlying: Common Stock · 137,000 shares Expires 2031-02-03 F1 · derivative.exercise_date: 12.5% of the shares subject to the stock option will vest and become exercisable on the six-month anniversary of the grant date listed in column 3 above, and the remaining shares will vest in 42 equal monthly installments thereafter. Read SEC document |
| April 13, 2019 Filed Apr 15, 2019 20:08 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Exercise / conversionRestricted Stock Units · Derivative | 6,875 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001179110-19-004936 · edgar.xml · derivative · entry 3 LEONHARDT HARRY J · CIK 0001286102 · SVP, GC 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,875 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: This transaction represents the vesting and settlement of restricted stock units in shares of common stock of the Issuer. F2 · derivative.expiration_date: This transaction represents the vesting and settlement of restricted stock units in shares of common stock of the Issuer. Read SEC document |
| April 13, 2019 Filed Apr 15, 2019 20:08 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Tax withholdingCommon Stock | 2,377 | $16.54 | $39,315.58 |
DisclosureSEC source: 0001179110-19-004936 · edgar.xml · nonDerivative · entry 2 LEONHARDT HARRY J · CIK 0001286102 · SVP, GC 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,373 F1 · shares: The reported disposition of 2,377 shares represents the shares that were withheld by the Issuer as payment for minimum statutory tax withholding requirements. Read SEC document |
| April 13, 2019 Filed Apr 15, 2019 20:08 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Exercise / conversionCommon Stock | 6,875 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-19-004936 · edgar.xml · nonDerivative · entry 1 LEONHARDT HARRY J · CIK 0001286102 · SVP, GC 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,750 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 22, 2019 Filed Feb 23, 2019 00:03 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Exercise / conversionRestricted Stock Units · Derivative | 11,392 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001179110-19-002464 · edgar.xml · derivative · entry 3 LEONHARDT HARRY J · CIK 0001286102 · SVP, GC 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,784 Underlying: Common Stock · 11,392 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: This transaction represents the vesting and settlement of restricted stock units in shares of common stock of the issuer. F2 · derivative.expiration_date: This transaction represents the vesting and settlement of restricted stock units in shares of common stock of the issuer. Read SEC document |
| February 22, 2019 Filed Feb 23, 2019 00:03 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Tax withholdingCommon Stock | 3,939 | $16.81 | $66,214.59 |
DisclosureSEC source: 0001179110-19-002464 · edgar.xml · nonDerivative · entry 2 LEONHARDT HARRY J · CIK 0001286102 · SVP, GC 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,875 F1 · shares: The reported disposition of 3,939 shares represents the shares that were withheld by the issuer as payment for tax withholding obligations. Read SEC document |
| February 22, 2019 Filed Feb 23, 2019 00:03 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Exercise / conversionCommon Stock | 11,392 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-19-002464 · edgar.xml · nonDerivative · entry 1 LEONHARDT HARRY J · CIK 0001286102 · SVP, GC 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,814 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 14, 2019 Filed Feb 15, 2019 22:34 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Exercise / conversionRestricted Stock Units · Derivative | 7,809 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001179110-19-002006 · edgar.xml · derivative · entry 3 LEONHARDT HARRY J · CIK 0001286102 · SVP, GC 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,425 Underlying: Common Stock · 7,809 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: This transaction represents the vesting and settlement of restricted stock units in shares of common stock of the issuer. F2 · derivative.expiration_date: This transaction represents the vesting and settlement of restricted stock units in shares of common stock of the issuer. Read SEC document |
| February 14, 2019 Filed Feb 15, 2019 22:34 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Tax withholdingCommon Stock | 2,700 | $16.54 | $44,658.00 |
DisclosureSEC source: 0001179110-19-002006 · edgar.xml · nonDerivative · entry 2 LEONHARDT HARRY J · CIK 0001286102 · SVP, GC 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,422 F1 · shares: The reported disposition of 2,700 shares represents the shares that were withheld by the issuer as payment for tax withholding obligations. Read SEC document |
| February 14, 2019 Filed Feb 15, 2019 22:34 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Exercise / conversionCommon Stock | 7,809 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-19-002006 · edgar.xml · nonDerivative · entry 1 LEONHARDT HARRY J · CIK 0001286102 · SVP, GC 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,122 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 12, 2019 Filed Feb 14, 2019 23:26 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | GrantRestricted Stock Units · Derivative | 37,538 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001179110-19-001933 · edgar.xml · derivative · entry 2 LEONHARDT HARRY J · CIK 0001286102 · SVP, GC 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,538 Underlying: Common Stock · 37,538 shares Expires not disclosed F2 · derivative.exercise_date: This award vests one-fourth on the first anniversary of the grant date then one-fourth on each anniversary date thereafter. F2 · derivative.expiration_date: This award vests one-fourth on the first anniversary of the grant date then one-fourth on each anniversary date thereafter. Read SEC document |
| February 12, 2019 Filed Feb 14, 2019 23:26 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | GrantOption to Purchase Common Stock · Derivative | 71,602 | $0.00 Strike: $16.65 | $0.00 |
DisclosureSEC source: 0001179110-19-001933 · edgar.xml · derivative · entry 1 LEONHARDT HARRY J · CIK 0001286102 · SVP, GC 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,602 Underlying: Common Stock · 71,602 shares Expires 2029-02-12 F1 · derivative.exercise_date: This option vests one-fourth on such date and then 1/48th monthly thereafter. Read SEC document |
| February 03, 2019 Filed Feb 5, 2019 21:11 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Exercise / conversionRestricted Stock Units · Derivative | 15,413 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001179110-19-001318 · edgar.xml · derivative · entry 3 LEONHARDT HARRY J · CIK 0001286102 · SVP, GC 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,413 Underlying: Common Stock · 15,413 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: This transaction represents the vesting and settlement of restricted stock units in shares of common stock of the issuer. F2 · derivative.expiration_date: This transaction represents the vesting and settlement of restricted stock units in shares of common stock of the issuer. Read SEC document |
| February 03, 2019 Filed Feb 5, 2019 21:11 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Tax withholdingCommon Stock | 5,658 | $16.12 | $91,206.96 |
DisclosureSEC source: 0001179110-19-001318 · edgar.xml · nonDerivative · entry 2 LEONHARDT HARRY J · CIK 0001286102 · SVP, GC 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,313 F1 · shares: The reported disposition of 5,658 shares represents the shares that were withheld by the issuer as payment for tax withholding obligations. Read SEC document |
| February 03, 2019 Filed Feb 5, 2019 21:11 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Exercise / conversionCommon Stock | 15,413 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-19-001318 · edgar.xml · nonDerivative · entry 1 LEONHARDT HARRY J · CIK 0001286102 · SVP, GC 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,971 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 13, 2018 Filed Apr 13, 2018 23:15 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Exercise / conversionRestricted Stock Units · Derivative | 6,875 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001179110-18-005645 · edgar.xml · derivative · entry 3 LEONHARDT HARRY J · CIK 0001286102 · SVP, GC and CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,875 Underlying: Common Stock · 6,875 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: This transaction represents the vesting and settlement of restricted stock units in shares of common stock of the Issuer. F2 · derivative.expiration_date: This transaction represents the vesting and settlement of restricted stock units in shares of common stock of the Issuer. Read SEC document |
| April 13, 2018 Filed Apr 13, 2018 23:15 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Tax withholdingCommon Stock | 2,377 | $19.37 | $46,042.49 |
DisclosureSEC source: 0001179110-18-005645 · edgar.xml · nonDerivative · entry 2 LEONHARDT HARRY J · CIK 0001286102 · SVP, GC and CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,558 F1 · shares: The reported disposition of 2,377 shares represents the shares that were withheld by the Issuer as payment for minimum statutory tax withholding requirements. Read SEC document |
| April 13, 2018 Filed Apr 13, 2018 23:15 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Exercise / conversionCommon Stock | 6,875 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-18-005645 · edgar.xml · nonDerivative · entry 1 LEONHARDT HARRY J · CIK 0001286102 · SVP, GC and CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,935 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 22, 2018 Filed Feb 23, 2018 22:14 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Exercise / conversionRestricted Stock Units · Derivative | 11,392 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001179110-18-002768 · edgar.xml · derivative · entry 3 LEONHARDT HARRY J · CIK 0001286102 · SVP, GC and CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,176 Underlying: Common Stock · 11,392 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: This transaction represents the vesting and settlement of restricted stock units in shares of common stock of the issuer. F2 · derivative.expiration_date: This transaction represents the vesting and settlement of restricted stock units in shares of common stock of the issuer. Read SEC document |
| February 22, 2018 Filed Feb 23, 2018 22:14 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Tax withholdingCommon Stock | 3,939 | $19.28 | $75,943.92 |
DisclosureSEC source: 0001179110-18-002768 · edgar.xml · nonDerivative · entry 2 LEONHARDT HARRY J · CIK 0001286102 · SVP, GC and CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,060 F1 · shares: The reported disposition of 3,939 shares represents the shares that were withheld by the issuer as payment for tax withholding obligations. Read SEC document |
| February 22, 2018 Filed Feb 23, 2018 22:14 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Exercise / conversionCommon Stock | 11,392 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-18-002768 · edgar.xml · nonDerivative · entry 1 LEONHARDT HARRY J · CIK 0001286102 · SVP, GC and CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,999 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 14, 2018 Filed Feb 16, 2018 21:09 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | GrantRestricted Stock Units · Derivative | 31,234 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001179110-18-002259 · edgar.xml · derivative · entry 2 LEONHARDT HARRY J · CIK 0001286102 · SVP, GC and CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,234 Underlying: Common Stock · 31,234 shares Expires not disclosed F2 · derivative.exercise_date: This award vests one-fourth on the first anniversary of the grant date then one-fourth on each anniversary date thereafter. F2 · derivative.expiration_date: This award vests one-fourth on the first anniversary of the grant date then one-fourth on each anniversary date thereafter. Read SEC document |
| February 14, 2018 Filed Feb 16, 2018 21:09 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | GrantOption to Purchase Common Stock · Derivative | 54,780 | $0.00 Strike: $18.41 | $0.00 |
DisclosureSEC source: 0001179110-18-002259 · edgar.xml · derivative · entry 1 LEONHARDT HARRY J · CIK 0001286102 · SVP, GC and CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,780 Underlying: Common Stock · 54,780 shares Expires 2028-02-14 F1 · derivative.exercise_date: This option vests one-fourth on such date and then 1/48th monthly thereafter. Read SEC document |
| February 03, 2018 Filed Feb 5, 2018 21:27 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Exercise / conversionRestricted Stock Units · Derivative | 15,413 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001179110-18-001495 · edgar.xml · derivative · entry 3 LEONHARDT HARRY J · CIK 0001286102 · SVP, GC and CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,826 Underlying: Common Stock · 15,413 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: This transaction represents the vesting and settlement of restricted stock units in shares of common stock of the issuer. F2 · derivative.expiration_date: This transaction represents the vesting and settlement of restricted stock units in shares of common stock of the issuer. Read SEC document |
| February 03, 2018 Filed Feb 5, 2018 21:27 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Tax withholdingCommon Stock | 5,605 | $18.37 | $102,963.85 |
DisclosureSEC source: 0001179110-18-001495 · edgar.xml · nonDerivative · entry 2 LEONHARDT HARRY J · CIK 0001286102 · SVP, GC and CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,607 F1 · shares: The reported disposition of 5,605 shares represents the shares that were withheld by the issuer as payment for tax withholding obligations. Read SEC document |
| February 03, 2018 Filed Feb 5, 2018 21:27 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Exercise / conversionCommon Stock | 15,413 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-18-001495 · edgar.xml · nonDerivative · entry 1 LEONHARDT HARRY J · CIK 0001286102 · SVP, GC and CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,212 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 13, 2017 Filed Apr 14, 2017 18:03 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Exercise / conversionRestricted Stock Units · Derivative | 6,875 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001179110-17-005998 · edgar.xml · derivative · entry 3 LEONHARDT HARRY J · CIK 0001286102 · SVP, GC and CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,750 Underlying: Common Stock · 6,875 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: This transaction represents the vesting and settlement of restricted stock units in shares of common stock of the Issuer. F2 · derivative.expiration_date: This transaction represents the vesting and settlement of restricted stock units in shares of common stock of the Issuer. Read SEC document |
| April 13, 2017 Filed Apr 14, 2017 18:03 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Tax withholdingCommon Stock | 2,583 | $12.81 | $33,088.23 |
DisclosureSEC source: 0001179110-17-005998 · edgar.xml · nonDerivative · entry 2 LEONHARDT HARRY J · CIK 0001286102 · SVP, GC and CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,799 F1 · shares: The reported disposition of 2,583 shares represents the shares that were withheld by the Issuer as payment for minimum statutory tax withholding requirements. Read SEC document |
| April 13, 2017 Filed Apr 14, 2017 18:03 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Exercise / conversionCommon Stock | 6,875 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-17-005998 · edgar.xml · nonDerivative · entry 1 LEONHARDT HARRY J · CIK 0001286102 · SVP, GC and CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,382 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 22, 2017 Filed Feb 24, 2017 21:06 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | GrantRestricted Stock Units · Derivative | 45,568 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001179110-17-003120 · edgar.xml · derivative · entry 2 LEONHARDT HARRY J · CIK 0001286102 · SVP, GC and CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,568 Underlying: Common Stock · 45,568 shares Expires not disclosed F2 · derivative.exercise_date: This award vests one-fourth on the first anniversary of the grant date then one-fourth on each anniversary date thereafter. F2 · derivative.expiration_date: This award vests one-fourth on the first anniversary of the grant date then one-fourth on each anniversary date thereafter. Read SEC document |
| February 22, 2017 Filed Feb 24, 2017 21:06 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | GrantOption to Purchase Common Stock · Derivative | 72,925 | $0.00 Strike: $12.07 | $0.00 |
DisclosureSEC source: 0001179110-17-003120 · edgar.xml · derivative · entry 1 LEONHARDT HARRY J · CIK 0001286102 · SVP, GC and CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,925 Underlying: Common Stock · 72,925 shares Expires 2027-02-22 F1 · derivative.exercise_date: This option vests one-fourth on such date and then 1/48th monthly thereafter. Read SEC document |
| February 03, 2017 Filed Feb 7, 2017 00:01 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Exercise / conversionRestricted Stock Units · Derivative | 15,413 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001179110-17-001810 · edgar.xml · derivative · entry 3 LEONHARDT HARRY J · CIK 0001286102 · SVP, GC and CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,239 Underlying: Common Stock · 15,413 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: This transaction represents the vesting and settlement of restricted stock units in shares of common stock of the issuer. F2 · derivative.expiration_date: This transaction represents the vesting and settlement of restricted stock units in shares of common stock of the issuer. Read SEC document |
| February 03, 2017 Filed Feb 7, 2017 00:01 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Tax withholdingCommon Stock | 6,198 | $12.26 | $75,987.48 |
DisclosureSEC source: 0001179110-17-001810 · edgar.xml · nonDerivative · entry 2 LEONHARDT HARRY J · CIK 0001286102 · SVP, GC and CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,507 F1 · shares: The reported disposition of 6,198 shares represents the shares that were withheld by the issuer as payment for tax withholding obligations. Read SEC document |
| February 03, 2017 Filed Feb 7, 2017 00:01 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Exercise / conversionCommon Stock | 15,413 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-17-001810 · edgar.xml · nonDerivative · entry 1 LEONHARDT HARRY J · CIK 0001286102 · SVP, GC and CCO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,705 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.